Results 171 to 180 of about 38,538 (308)

Bispecific and multispecific immune engagers for redirecting innate and adaptive immunity against hematologic cancers. [PDF]

Discov Oncol
Ardah MT, Abdulsahib WK, Jasim IK, Malathi H, Patro PS, Anand DA, Mukherjee G, Sinha A, Aminqulov S.   +8 more
europepmc   +1 more source

T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies [PDF]

, 2017
Arber, Caroline, Bonifant, Challice Lee, Cooper, Laurence J. N., Gerken, Claudia, Gottschalk, Stephen, Iwahori, Kota, Kakarla, Sunitha, Rodriguez-Cruz, Tania, Song, Xiao-Tong, Szöőr, Árpád, Torres, David, Velasquez, Mireya Paulina   +11 more
core   +1 more source

Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half‐Life FVIII versus Non‐FVIII Therapies

Haemophilia, EarlyView.
ABSTRACT Introduction The therapeutic landscape for patients with haemophilia A (PwHA) is rapidly evolving with the introduction of extended half‐life FVIII (EHL‐FVIII) and non‐FVIII therapies that mimic FVIII, such as emicizumab (EMI). Monitoring non‐factor therapies in the laboratory poses challenges; however, the thrombin generation assay (TGA) can ...
Jessica Garcia, Sean G. Yates, Ravi Sarode, Guy Young, Ayesha Zia   +4 more
wiley   +1 more source

Advances in multiple myeloma: key updates from the ASH 2025 meeting. [PDF]

J Hematol Oncol
Naing PT, Baljevic M.
europepmc   +1 more source

Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study

Haemophilia, EarlyView.
ABSTRACT Introduction Acquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan. Aim This post‐marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly
Midori Shima, Katsuyuki Fukutake, Yoshiyuki Ogawa, Yuta Kamei, Chiaki Sugita, Akinori Yuri, Ryota Kobayashi, Akiko Ioka, Tadashi Matsushita   +8 more
wiley   +1 more source

Parallel Sequencing of the Two Arms on a Bispecific Antibody by Electron Capture Dissociation on a timsOmni Platform Reveals Several By-products in the Controlled Fab-arm Exchange Process. [PDF]

Anal Chem
Stroganova I, Ollivier S, Radić L, Smyrnakis A, Kosmopoulou M, Schinkel J, Sliepen K, Greisch JF, Heck AJR.   +8 more
europepmc   +1 more source

Radionuclide Selection Influences Imaging Outcomes in Immuno-PET with a Brain-Penetrating Anti-Amyloid-β Antibody. [PDF]

J Nucl Med
Lopes van den Broek S, Bratteby K, Aguilar X, Tran TA, Syvänen S, Sehlin D.   +5 more
europepmc   +1 more source

Immune checkpoint inhibitor cardiomyotoxicity: a case series of five patients and development of a clinical management algorithm

Internal Medicine Journal, EarlyView.
Abstract Immune checkpoint inhibitor (ICI) therapies have revolutionised the management of a range of malignancies. However, the syndrome of ICI induced cardiomyotoxicity, also reported as triple “M” syndrome (myasthenia gravis, myositis and myocarditis) is an unfortunate severe consequence in up to 1%–2% of patients receiving ICI, with an associated ...
S. Z. Xie, J. E. Salem, A. Nagrial, A. Menzies, L. Thomas, S. Ramanathan, L. J. Berglund, S. C. Sasson, A. C. Grey, R. Habib, M. Wong, M. S. Carlino, B. Jeffrey, J. Mo, M. W. Lin   +14 more
wiley   +1 more source

Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritis. [PDF]

MAbs
Sims GP, Scaletta L, Andrews J, Sims DA, Strain M, Sigurdardottir A, Kuriakose T, England E, Rajasinghe L, Jiang F, Xiong X, Neal F, Vinall L, Newton P, Boger E, Kim C, Dahlbäck H, Prothon S, Leander J, Darrah E, Collins M, Douglas G, White N, Day K, Vousden KA, Huntington CE, Close D.   +26 more
europepmc   +1 more source

T cell targeting in cancer therapy [PDF]

, 1991
Bolhuis, R.L.H. (Reinder), Braakman, E. (Eric), Sturm, E. (E.)   +2 more
core   +1 more source